Background Oral metronomic therapy (OMV) is particularly suitable for palliative care, and schedules adapted for unfit patients are advisable. This study investigated the effects of oral vinorelbine given every other day without interruption and its pharmacokinetic profile in patients with advanced lung cancer. Materials and Methods Ninety-two patients received OMV at doses of 20, 30 or 50 mg. Toxic events, clinical benefit and overall survival were analysed. Blood pharmacokinetics were evaluated in 82 patients. Results Median treatment duration and overall survival were 15 (range 1.3-144) and 32.3 weeks, respectively; fourty-eight (60%) patients experienced clinical benefit. Outcomes were unrelated to previous therapies, age, histology or comorbidities. Toxicity was associated with higher blood concentrations of the drug. Pharmacokinetics were stable for up to two years, and were not influenced by treatment line or age. Conclusions OMV produced non-negligible survival in patients and also showed stable long-term blood concentrations. The schedule of 20-30 mg every other day without interruption gave good tolerability and clinical benefit.
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer : outcome and pharmacokinetics in the real world / F. Pasini, C. Barile, D. Caruso, Y. Modena, A. Fraccon, L. Bertolaso, D. Menon, F. La Russa, G. Crepaldi, A. Bononi, R. Spezzano, R. Padrini, G. Corona, M. Gusella. - In: INVESTIGATIONAL NEW DRUGS. - ISSN 1573-0646. - 36:5(2018 Oct), pp. 927-932. [10.1007/s10637-018-0631-8]
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer : outcome and pharmacokinetics in the real world
D. Caruso;R. Spezzano;
2018
Abstract
Background Oral metronomic therapy (OMV) is particularly suitable for palliative care, and schedules adapted for unfit patients are advisable. This study investigated the effects of oral vinorelbine given every other day without interruption and its pharmacokinetic profile in patients with advanced lung cancer. Materials and Methods Ninety-two patients received OMV at doses of 20, 30 or 50 mg. Toxic events, clinical benefit and overall survival were analysed. Blood pharmacokinetics were evaluated in 82 patients. Results Median treatment duration and overall survival were 15 (range 1.3-144) and 32.3 weeks, respectively; fourty-eight (60%) patients experienced clinical benefit. Outcomes were unrelated to previous therapies, age, histology or comorbidities. Toxicity was associated with higher blood concentrations of the drug. Pharmacokinetics were stable for up to two years, and were not influenced by treatment line or age. Conclusions OMV produced non-negligible survival in patients and also showed stable long-term blood concentrations. The schedule of 20-30 mg every other day without interruption gave good tolerability and clinical benefit.File | Dimensione | Formato | |
---|---|---|---|
Pasini_et_al-2018-Investigational_New_Drugs.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
498.6 kB
Formato
Adobe PDF
|
498.6 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pasini2018_Article_OralMetronomicVinorelbineOMVIn.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
498.99 kB
Formato
Adobe PDF
|
498.99 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.